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Criteria for vaccine introduction: results of a DELPHI discussion 
among international immunisation experts on a stepwise decision-
making procedure 
 
Abstract 
 
Background: Based on a model of a stepwise approach for decision-making on vaccine introduction, 
this study aimed to reveal unpublished decision aids, to assess cut-off limits or thresholds for vaccine 
introduction that have already been used, and to discuss the comprehensiveness and feasibility of our 
suggested model. 
 
Methods: 40 international immunisation experts were invited to a DELPHI discussion, 14 finally 
participated. Experts received a questionnaire and were asked for comments on other experts’ opinions 
and specification of their previously given answers in the second DELPHI round. We did not aim at 
developing a consensus document. 
 
Results: Though most of the DELPHI participants were not aware of decision aids other than the five 
that had been used for the development of our model, the international discussion revealed four 
additional national documents that define decision-making criteria. Except for one example with a 
cost-utility ratio, no defined thresholds or cut-off limits have been used in vaccine introduction 
decisions so far. The majority of experts believe that a stepwise approach could enhance the feasibility 
of decision-aids. The experts agreed that the influence of each single criterion of our model should be 
at least “important” for decision-making. The most often mentioned possible negative consequence 
that could arise from a rigid stepwise procedure, was a delay of the vaccine introduction process. 
 
Conclusions: The suggested stepwise procedure provides a systematic and evidence based 
standardised way to support public health immunisation policy decisions. A framework could be a 
common starting point.  
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Abstrakt 
Hintergrund: Basierend auf einem Stufenmodell für Entscheidungen zur Implementierung von 
Impfungen in nationale Impfprogramme hat diese Arbeit folgende Zielsetzungen: nicht publizierte 
Entscheidungshilfen zu identifizieren sowie Grenzwerte zu erheben, die bereits verwendet wurden 
(z.B. Kosten-Nutzen Grenzwerte bis zu dem eine Impfung als finanzierungswürdig gilt) als auch die 
Vollständigkeit und Anwendbarkeit eines Stufenmodells für Impfentscheidungen zu diskutieren.  
 
Methoden: 40 internationale Impfexperten wurden zu einer DELPHI Diskussion eingeladen, 14 
nahmen daran teil. Die Teilnehmer erhielten einen Fragebogen und wurden danach gebeten in einer 
zweiten Runde die gesammelten Aussagen der anderen Teilnehmer zu kommentieren, bzw. ihre 
eigenen Aussagen zu spezifizieren. Die Erstellung eines Konsensusdokuments wurde dabei nicht 
angestrebt. 
 
Ergebnisse: Durch die internationale Diskussion  konnten vier weitere nationale Dokumente 
identifiziert werden, welche Entscheidungskriterien definieren. Mit Ausnahme eines Schwellenwertes 
für Kosten-Nutzen Verhältnisse  wurden keine anderen definierten Grenzwerte bisher in 
Implementierungsentscheidungen berücksichtigt. Die Mehrzahl der Experten stimmte überein, dass 
ein stufenweises Vorgehen die Anwendbarkeit von Entscheidungshilfen erhöhen kann. Sie gaben an, 
dass im Entscheidungsprozess alle 14 Kriterien unseres Modells zumindest „wichtig“ wären. Die am 
häufigsten genannte potentielle negative Folge eines unflexiblen stufenweisen Vorgehens war die 
Verzögerung des Entscheidungsprozesses. 
 
Schlussfolgerungen: Das vorgeschlagene Stufenmodell für Impfentscheidungenbietet eine 
standardisierte und evidenz-basierte Möglichkeit, öffentliche Impfpolitikentscheidungen zu 
unterstützen. Ein Rahmengerüst könnte ein gemeinsamer Ansatzpunkt sein. 
 
This abstract is provided by the authors, and is for convenience of the users only. The author certifies 
that the translation faithfully represents the official version in the language of the journal, which is the 
published Abstract of record and is the only Abstract to be used for reference and citation. 
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 3 
Introduction 
Some of the vaccines that are currently developed or have been introduced within the last 
years target at the prevention of less widespread, less severe and often chronic diseases at all 
age groups rather than severe infectious childhood diseases. Concurrently, they are more 
expensive than some of the even “cost-saving old vaccines”. In an era of rising healthcare 
costs, cost-effectiveness of vaccination programs on the population level is increasingly taken 
into consideration. Consecutively Health Technology Assessment (HTA) became an 
important tool to support decision makers whether or not to introduce a new health 
technology- including vaccines (Hutt 2008). Except for a few countries, like the UK for 
example, HTA based decisions are still rare and despite of efforts being undertaken by the 
European Union, vaccination policies are moreover exclusively defined on national levels 
(Lopalco 2010). Therefore it is not astonishing that national immunisation programs differ 
from country to country in their vaccination schedules and decisions regarding the 
implementation and funding of new vaccines. Assuming that decisions on vaccine 
introduction should be unbiased, comprehensive and systematic and therefore be based on 
deliberate, rational, comprehensible and evidence based criteria, we asked ourselves if 
decision aids concerning rational vaccine introduction exist at all and which criteria are 
crucial for a rational decision-making process. Therefore we prepared a report assessing the 
availability of decision tools (Piso and Wild 2009). The comparison of the five decision aids 
or analytical frameworks (Stratton et al. 2000; Kimman et al. 2006; Erickson et al. 2005; 
World Health Organization 2005; Mansoor et al. 2000) that had been identified revealed an 
overall similarity with some differences in the approach as well as the criteria: Burden of 
disease and vaccine characteristics play a key role in all decision-making processes. Because 
cost-effectiveness analyses are influenced by various factors and have several limitations, 
views on its significance vary. Other relevant factors include the immunisation program itself 
as well as its conformity with other programs, its feasibility and how easily it can be 
evaluated. Additionally acceptability, equity as well as ethical, legal and political 
considerations have been mentioned, though they have been discussed to highly differing 
extents. As a result of the literature comparison we suggested a practical, stepwise approach 
(table 1) for advisers and decision makers on vaccination policy to use as a basis for vaccine 
introduction decisions, because we assumed that the most comprehensive framework possible 
would not provide a feasible tool for decision makers.  
- please insert table 1 here - 
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The aims of this DELPHI discussion were to reveal eventually unpublished knowledge (further 
decision aids or introduction guidelines), to assess cut-off limits or thresholds (e.g. for  costs, burden 
of disease or vaccine safety) that have already been used for vaccine introduction decisions in 
industrialised countries and to discuss our model of a stepwise decision-making approach. We did not 
aim at developing a consensus document. 
 
Methods 
We invited 40 international immunisation experts in 16 industrialised countries whom we had 
identified by contacting international HTA agencies to participate in a DELPHI discussion. 16 experts 
(in 10 countries) agreed to participate and received the first questionnaire by email. The questionnaire 
had been developed by two members of our institution and tested for feasibility and comprehensibility 
within our team. It consisted of two questions on expert’s affiliation and immunisation expertise, two 
questions on identification of further decision aids, five questions on cut-off limits used in vaccine 
introduction decision-making and three questions to discuss our proposed stepwise decision-making 
model. Despite a reminder that we sent out one week before closure, only 50% of the experts returned 
their questionnaires by the end of the first deadline. Therefore the deadline was slightly expanded and 
participants were invited again individually. Nine weeks after the start of the first DELPHI round we 
extracted data of 13 completed questionnaires into an Excel sheet and SPSS database. We generated 
the first anonymous summary report and redistributed it to the participants for further comments. 
Additionally we added three questions on applicability of DELPHI results and rational decision-
making processes in general. Keeping in mind that the study was not aiming at a consensus document, 
experts were not asked to reconsider their previously given answers taking other experts’ views into 
consideration (and answer the same questions again- in line with the commonly used DELPHI 
method). Experts were rather asked for comments on other experts’ opinions and specification of their 
previously given answers wherever necessary and reasonable. Finally 12 completed questionnaires 
could be analysed. 
 
Results 
Participants 
From 14 DELPHI participants five work at a research institute, none work in the vaccine industry or in 
an international organisation (e.g. WHO). One is a national politician, five are members of national 
immunisation committees (affiliation and country of participants table 2). Nine have already 
participated in national vaccine implementation decision-making, six in the preparation phase prior to 
the final decision-making and three in decision-making process research.  
 
- please insert table 2 here -  
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 5 
Identification of further decision aids 
Most of the experts stated that they didn’t know of any other publications than the five previously 
analysed documents (Piso and Wild 2009) that aim at rational vaccine implementation decision-
making in industrialized countries. Nevertheless three further documents could be identified by 
DELPHI participants: a Brazilian (Castillo-Solórzano and Andrus 2004) publication that deals with 
decision-making on the development of new vaccines, an Australian document (Australian 
Government Department of Health and Ageing Pharmaceutical Benefits Advisory Committee 2008), 
that aims at rational medicine implementation decision-making and a Spanish document (González 
Alonso et al. 2004), which points out the main criteria that can be taken into account to introduce any 
change in the vaccination program. The latter criteria are related to the burden of disease, intrinsic 
factors of the vaccine, the cost effectiveness of the vaccine, the impact of the new vaccine for the 
vaccination scheme and other aspects such as acceptability as well as equity and legal considerations. 
Additionally, in the pre-Delphi phase one further document had been revealed by a member of the 
Dutch HTA agency (Houweling et al. 2010) . In this report seven criteria for the inclusion of 
vaccinations in public programmes have been defined. These criteria cover the seriousness and extent 
of the disease burden, the effectiveness and safety of the vaccination as well as the acceptability, the 
efficiency (favourable cost-benefit ratio in relation to alternative measures) and the priority of the 
vaccination (urgency of the public health need). 
The majority of experts also didn’t know of (un)published guidelines or institutional manuals, only 
one referred to the existence of “unpublished national guidelines” in her own country. The two 
Australian experts referred to proformas that communicate advice on decision-making between peak 
bodies: one is based on a structured set of questions agreed between the two bodies (committees) and 
precedes an application for funding within the national immunisation program; the other responds to 
specific technical questions about the application following a preliminary review of the application.  
Each proforma is completed by the technical advisory committee and is considered by the 
recommending committee.  Each completed proforma is also provided to the relevant applicant, who 
can comment on the information provided before any recommendation is considered. 
 
Identification of cut-off limits or thresholds that have already been used in the decision-making 
process 
Cost-utility threshold ($/QALY, €/QALY) 
Vaccines have been considered to be favourable because they showed a cost-utility ratio below a 
defined threshold just in one country (about 50.000 US$ or 35.000€/ QALY). One expert referred to 
an implied threshold (from about 30.000 US$/ 22.000€ to 57.000 US$/ 40.000€ per life year saved), 
that was derived from a retrospective study which analysed the consistency of funding decisions 
during a given time period (George et al. 2001). Other experts didn’t give any defined thresholds but 
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 6 
stated, that cost-utility data were somehow considered and that thresholds may differ according to 
various and changing economic situations.  
Domestic burden of disease 
The majority of experts stated that criteria related to the burden of disease have been used (e.g.: 
epidemiology, clinical manifestations, mortality, costs, social impact, hospitalisation, medical 
attendance or disease sequelae). Most of them agreed that there were neither defined “cut-off limits” 
nor a predefined minimal burden of disease.  
Effectiveness 
Most experts pointed out, that no quantitative cut-off levels of proposed vaccine effectiveness have 
been used, “although effectiveness is considered separately as a “building block" of the overall 
assessment”. They explained that effectiveness is “incorporated in the cost-effectiveness model”, “a 
relevant factor in its own right” and “is considered more in the context of overall analysis, including a 
sensitivity analysis”. Vaccine effectiveness is also “considered in vaccine development” and a cut-off 
limits would “depend on the disease for which the vaccination is proposed”. One expert mentioned 
that “an efficacy less than 70% would be questionable”, whereas another one stated that an efficacy of 
50% may be acceptable. In the second DELPHI round one expert pointed out, that efficacy thresholds 
should primarily depend on the outcome being measured (e.g. immunogenicity outcome vs. directly 
patient-relevant outcome). 
Safety  
None of the experts gave a defined “safety level” but some referred to safety issues that have been 
considered in vaccine introduction decision-making: thus, safety is for example “taken into account in 
the cost effectiveness model” and “depends on the risk/benefit balance and the absence of related 
serious adverse events”. One expert defined safety as “registered by the national medical products 
agency”. Another expert stated in the discussion that “safety versus efficacy has a changing value with 
respect to the severity of the disease and that saftey considerations have a much higher ranking in 
socioeconomically well situated countries”. 
Number needed to vaccinate 
Except for two experts who gave examples in which the number needed to vaccinate (NNV) has 
already been used as decision criterion (in HPV and Herpes Zoster vaccination decisions), most 
experts agreed, that no defined number needed to vaccinate (NNV) has been used. They see the NNV 
“incorporated into the cost effectiveness model” or as “one measure of vaccine effectiveness”. Still, 
“the interpretation of an effectiveness outcome should depend on the nature of the outcome being 
presented”. For example, “the NNV to get an extra immunological response should be interpreted 
differently to the NNV to avoid one extra death”. Additionally, “the NNV should always include the 
time frame of observation (e.g. three months vs. twenty years)”.  In case of “vaccines preventing non 
communicalbe diseases (e.g. Tetanus) that provide personal protection only, each immunised 
individual may benefit”. By contrast, in communicable diseases herd effects have to be taken into 
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 7 
NNV considerations:  “The example of rubella vaccination for the prevention of congenital rubella 
syndrome has shown that a too low immunisation rate may have worse effects than no vaccination.” 
Discussion of the criteria to be taken into consideration and the suggested stepwise procedure  
None of the DELPHI participants considered the listed criteria (table 1) redundant. Only three experts 
added criteria for rational decision-making that they assumed to be missing in the synthesis of the 
decision support document (Piso and Wild 2009): the “impact on current disease management or 
prevention” and “immunological interference with other vaccines or the effect on risk behaviour that 
might increase risk of other diseases spread” were mentioned though these considerations had already 
been covered by the side-effects criterion (see step 4 in table 1). Also, the “need for re-evaluation of 
decision, especially when long-term effects are unknown at initial decision point” was added, though 
the last step of the decision-making model already emphasises the need of re-evaluation of decisions. 
Furthermore the “importance of uncertainties” was mentioned, though they should be considered in 
step 1 in the field of research questions (that have not been answered sufficiently at the time of 
decision-making).  
 
The majority of participants agreed that there are no general more or less important criteria to be 
fulfilled or considered in the decision-making process.  Others pointed out that “disease burden is 
most important regardless of (reasonable) costs” or in contrast, an “acceptable incremental cost-
effectiveness, preferably with minimal uncertainty” is the most important decision criterion.  Other 
major considerations mentioned were, “associated risks”, “vaccine production capacity” and “any 
hurdles for marketing a vaccine”. The latter should even be discussed, before large trials are initiated. 
 
Next, participants ranked the 14 criteria, that had been identified in our decision support paper (Piso 
and Wild 2009), dependent on the influence these criteria should have on vaccine introduction 
decisions on a scale between 1 (very important) and 5 (not important). The median of grades ranged 
from 1 to 3, therefore experts agreed that the influence of each single criterion should at least be 
“important” (table 3). “Burden of disease”, “Vaccine”, “Side effects” and “Ethical considerations” 
were considered to be most important (median 1.0). 
 
- please insert table 3 here - 
 
The majority of experts argued that this ranking is dependent on the type of vaccine and the disease 
against it is introduced, respectively. They acknowledged that the “importance of criteria is variable 
depending on the individual case, especially the severity of the disease, whether there is already a 
vaccine available for the intended purpose or not” and that it is “dependant on the type of vaccine (e.g. 
attenuated or live)”. Examples of crucial criteria that led to a decision to introduce or to withhold a 
vaccine from a national immunisation program in the past were given by almost all participants, e.g.:  
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 8 
- “the burden of disease and the increasing number of cases” (meningococcal C vaccine), 
- “epidemiology and sequalae” (herpes zoster vaccine),  
- “high hospitalization rate” (rotavirus vaccine),  
- “political considerations” (human papilloma virus and herpes zoster vaccine),  
- “health economic aspects” (pneumococcal vaccine),  
- “price negotiations due to an unfavourable incremental cost-effectiveness ratio” (human 
papilloma virus vaccine),  
- “side effects” (vaccines against tuberculosis or polyomyelitis),  
- “a lower than expected efficacy” (hexavalent vaccine against diphtheria, tetanus, pertussis, 
hepatitis B, poliomyelitis and Haemophilus influenzae type b) as well as   
- “issues that relate to long term effects of vaccination and the number of areas of uncertainty" 
(herpes zoster and varicella vaccine). 
 
The majority of experts believe that a stepwise approach could enhance the feasibility of decision-aids. 
Most of them even stated that the order and the hierarchy of steps and the criteria themselves should 
not be changed or moved to a different step. While one participant suggested to change the order of 
steps 3 and 4 vice versa, another participant disagreed in the discussion, because he stated: “the reason 
to have a logical order was to help ensure consistent decision-making over time” and “all the 
influential information of steps 1-4 must be taken into consideration for the decision in step 5” 
anyway. “The presentation of information in a consistent order” would be “crucial to efficient 
decision-making in a systematic manner across a series of health care interventions”. Another 
participant suggested, that “HTA agencies need to get involved in a step 0, deciding together with 
efficacy and safety agencies on primary endpoints and criteria to reach before the starting of large 
phase 3 trials”. In the discussion a different expert commented this suggestion as “laudable”, but 
pointed out that also HTA agencies may want to change their position during the following years, 
especially “if the lead time to a return on investment is many years during which time the 
understanding of the disease may move on”. Another expert mitigated the role of HTA agencies by 
stating that “HTA agencies are but one part of the decision-making process”. Another expert 
highlighted “the need for re-evaluation and repetition of the stepwise evaluation as soon as data 
become available, especially if the results are long-term”. The conclusion that “many steps are 
dependant on each other and cannot only be considered alone” was reassured by a different 
participant in the discussion. 
 
Most experts gave reasons for situations in which one or more steps have been or would likely to be 
skipped. “If planning is reactive rather than proactive, political interests” might have a greater 
influence on vaccine introduction “than evidence-based criteria”. Health economic considerations 
might be less important if a “vaccine for a frequent short term life-threatening disease is effective (e.g. 
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pandemic)”. The “immediacy of a problem” might be high, therefore one “may not be able to wait 
until all data is available”. The “public health relevance of disease prevention and prevention of its 
consequences” might be considered “more important than the burden of disease” (for the individual). 
Another expert thought, that “step 1 could sometimes come after step 2, as the availability of a new 
vaccine from a vaccine manufacturer has sometimes been the impetus to assess the public health 
burden of disease.” 
 
Half of the participants thought that no negative consequences could arise from a stepwise procedure 
“unless the steps were too rigidly implemented” and it was not “necessary to cover one step before 
going to the next one”. The other half mentioned possible negative consequences, most often “a delay 
of the vaccine introduction process”. This aspect was considered “serious with respect to the 
everywhere growing administrative burocracy”. One the other hand one participant totally disagreed 
that a stepwise procedure would lead to a delay and endorsed that it is even “a way to have a more 
organised process”. 
 
All experts see strengths of the proposed model. It is “complete and logical” and therefore “its 
comprehensiveness and thoroughness helps, that all relevant factors are appropriately considered and 
addressed“. Its “clarity and structure may help to avoid mistakes” and it enhances “transparency”.  It 
provides a “systematic and evidence based standardised way (“a tool”) to support public health policy 
decision.” It was seen to be “easy to repeat” and therefore easy to “compare with others”. 
  
A potential weakness of the model could be that it “may need to be flexible in a public health 
emergency”.  Additionally, a stepwise decision-making tool could be “weaker than political and 
economic rationalities” and “too exhaustive for busy decision makers”. Furthermore, there “may not 
be adequate data to access all factors” and “even within one healthcare system” people “may weigh 
the factors differently, leading to disagreements.”  One expert mentioned that the decision-making tool 
“may not accurately encompass particular characteristics of a new intervention”. Therefore he stated 
that “a deliberative committee process” would be more relevant for decision makers “than applying a 
formulaic approach to decision-making.” 
 
Discussion 
Though most of the DELPHI participants were not aware of other decision aids, the international 
discussion revealed four additional national documents that define decision-making criteria. Except of 
one example for a cost-utility ratio, no defined thresholds or cut-off limits have been used in vaccine 
introduction decisions so far. All experts agreed that the influence of each single criterion of our model 
should be at least “important”. Almost all participants were convinced that a stepwise approach could 
enhance the feasibility of decision-aids.  
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All experts acknowledged that they gained some useful information by participating in the DELPHI 
discussion. Participation permitted them “to know other expert opinions and other documents used in 
other countries” and most of them thought that the information will be applicable in vaccine 
implementation discussion or decision-making they are involved in and it could even be used “to 
improve the own national guideline for the decision-making process”. Only one participant “detected 
nothing specific or unexpected which would be sufficient to form the basis of arguing for a change to 
the way they have already approached this issue in the national context”. 
 
The results of this Delphi discussion among international vaccination experts mainly reflects, what we 
all know, namely that “national immunisation programs are influenced by political and public opinion 
about money spending priorities and may not reflect health care priorities” and “many decisions have 
to be made when not all important information is available.” But nevertheless experts agreed that 
“guidelines may be helpful” to “articulate different rationalities” and to make the decision-making 
process “more evidence based than based on political considerations”. “Careful consideration of 
available evidence (“using defined criteria”), current context and ongoing discussions in a network of 
national and international experts” would at least  “help to make the best decisions regarding 
immunisation program planning”.  But even then decisions could only be “rational for a given context 
at a given point in time”.  “Identifying some areas of uncertainty” would not “mean a decision is not 
rational”, but the process would have to be “re-evaluated as more information is available”. 
 
Having said this, a more or less consistent structure on which vaccine implementation decisions are 
based on, could help all of us: vaccine industry would be supported in vaccine development and the 
following application procedure, if implementation criteria were transparent. Decision makers could 
insist on pre-defined information that has to be provided prior to the decision-making process. Last but 
not least, a clearly communicated decision would help health care workers as well as consumers to 
comprehend whether or not a vaccine has been implemented in a national program. Consequently, 
sharing all available information would make decisions on both levels- the population and the 
individual level- more evidence based rather than based on fear.  
 
The increasing number of vaccines implemented in programs on the one hand and the decreasing 
awareness of diseases that became less common due to successful vaccination programs already 
threatens program acceptability in the population. Therefore, only a structured, comprehensible 
decision-making process based on transparent decision criteria will strengthen vaccination as an 
effective public health tool in the future. 
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In this DELPHI discussion 14 experts from 10 industrialised countries, who have experience in the 
field of vaccine introduction decision making, gave insight to the basic principles of national decision-
making and its process. We did not aim at achieving a consensus document, though we would 
appreciate any efforts in this direction. In our opinion a consensus among decision makers could only 
be reached by discussions on a high political level, moderated by an international organisation (e.g. the 
WHO or the European Commission). It won’t be easily achieved whilst decision making criteria still 
show a wide range between countries or are even completely intransparent. Therefore the results of 
this DELPHI discussion could be a starting point for such efforts. 
 
Limitations 
Because of the small number of immunisation experts participating in this Delphi discussion, the 
quantitative analysis of the DELPHI results is not representative for the whole immunisation 
community. Results should rather be discussed in a qualitative manner. 
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Table 1: Suggested stepwise procedure for vaccine introduction decision making 
Step Criteria to be assessed* 
Step 1 Fundamental considerations concerning the disease as a public health problem and alternative 
operational and delivery strategies (alternative measures) 
1. aims of the planned immunisation strategy 
2. comparison with other programs (conformity of programs) 
3. availability of sufficient basic research data (research questions) 
Step 2 4. “disease” considerations, e.g.: 
– burden of disease  
– clinical manifestations 
– current treatment 
– epidemiology  
– risk groups and risk factors  
– social impact  
– other preventive measures 
5. “vaccine” considerations, e.g.: 
– vaccine characteristics 
– supply  
– administration schedule  
– immune response 
– efficacy and utilisation  
– population effectiveness 
– safety 
Step 3 6. cost-effectiveness analysis 
Step 4 7. considerations on acceptability and 
8. feasibility of the new program 
9. implications on equity 
10. ethical,  
11. legal and  
12. political considerations 
13. potential side effects (e.g.: vaccine side effects, feasibility side effects or utilization side 
effects) 
Step 5 decision making process itself (final decision) 
Step 6 implementation 
Step 7 14. surveillance  
– of vaccine coverage and utilisation  
– of epidemiologic changes, the frequency and nature of adverse events 
– and immune surveillance 
and re-evaluation (revision) 
*The consecutive numbers reflect the 14 criteria to be considered in a vaccine introduction decision making 
process that have been identified in our previous work (Piso and Wild 2009); key criteria in bold letters 
 
 
Table 2: Affiliation and country of DELPHI participants 
 
Institution Country 
National Centre for Immunisation Research & Surveillance (NCIRS) Australia 
Australian Government, Department of Health and Ageing Australia 
Medical University of Vienna, Insitute of Specific Prophylaxis and Tropical Medicine Austria 
National immunisation committee Austria 
Belgian Health Care Knowledge Centre (KCE) Belgium 
University of São Paulo Brazil 
McGill University Health Centre Canada 
National immunisation committee Germany 
Ministry of Health and Consumers Affairs, DG of Public Health Spain 
Junta de Andalucía, Departement of Health Spain 
The National Board of Health and Welfare, Communicable Disease Prevention and Control Sweden 
NHS Greater Glasgow and Clyde United Kingdom 
Immunisation Department of Health United Kingdom 
US Department of Veterans Affairs, National Center for Health Promotion and Disease Prevention USA 
 
 
 
 
 
Table
 2 
Table 3: Results of the criteria ranking (the influence each criterion should have in the decision 
making process) 
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Number 
valid 13 13 13 13 13 13 13 13 13 13 13 13 11 12 
missing 0 0 0 0 0 0 0 0 0 0 0 0 2 1 
Median 2.0 3.0 3.0 1.0 1.0 2.0 2.0 2.0 2.0 1.0 2.0 3.0 1.0 2.5 
Quartile 
Q1 1.5 2.0 2.0 1.0 1.0 2.0 2.0 1.5 1.0 1.0 2.0 2.5 1.0 2.0 
Q3 3.0 3.0 3.0 2.0 2.0 3.0 4.0 3.0 3.0 3.0 3.0 4.0 2.0 3.0 
 
Participants graded criteria from 1 (=very important) to 5 (=not important).The number of valid and missing 
answers as well as the median of results and their first (Q1)  and third (Q3) quartile are given.  
 
 
